Digital Biomarkers Market, By Type (Sensors, Wearable, Mobile based Applications, and Others), By Clinical Practice (Monitoring digital biomarkers, Diagnostic digital biomarkers, Predictive & Prognosis digital biomarkers, and Others), By Therapeutic Area (Neurological disorders, Cardiovascular diseases, Sleep & Movement disease, Diabetes, Respiratory disorders, and Others), By End-Users (Healthcare Providers, Payers, Biopharmaceutical Companies, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Market for digital biomarkers, estimated at US$ 4.8 billion in 2024, is expected to expand at a compound annual growth rate (CAGR) of 26.40% to US$ 40.1 billion by 2034.

Digital biomarkers are physiological and behavioral data that are objectively and quantitatively assessed using digital services such as implants, wearables, portables, and digestibles. Health-related outcomes are predicted, explained, or influenced by the gathered data. In addition, digital biomarkers are less expensive to measure, non-invasive, and modular.

One crucial aspect contributing to the target market's expansion is the increase in the use of smartphones and wearable technology. Healthcare is becoming more proactive rather than reactive because of digital biomarkers. The demand for digital biomarkers has grown as a result of the widespread use of wearable digital technology in healthcare and significant investments made in R&D. The COVID-19 pandemic has accelerated the digitization of the healthcare industry, which has increased financing and research for digital biomarker-driven medication discovery anticipated to propel the market for digital biomarkers to increase.